Cyclosporin as baseline immunosuppression in solid organ transplantation.

Cyclosporin as baseline immunosuppression in solid organ transplantation. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Cyclosporin as baseline immunosuppression in solid organ transplantation. Abstract Text:

M Winkler,

Cyclosporin is currently the basis of most immunosuppressive protocols after solid organ transplantation. In recent years a variety of new substances, such as tacrolimus, mycophenolate mofetil, sirolimus and everolimus (SDZ-RAD) have been developed. Besides these new immunosuppressants, which are structurally unrelated to cyclosporin, new formulations of cyclosporin have been introduced into the market. This review is intended to summarise the current knowledge on the use of cyclosporin as baseline immunosuppression after solid organ transplantation. Special emphasis is placed on comparison of cyclosporin-based immunosuppression with that by other recently introduced drugs that can be used as baseline immunosuppressants. Furthermore, the different formulations of cyclosporin are compared with each other. Finally, the optimal use of cyclosporin as baseline immunosuppressant in the early postoperative course as well as during long term immunosuppression is discussed from a practical perspective. During the past years a number of galenic formulations of cyclosporin with pharmacokinetic characteristics comparable to that of cyclosporin-modified-Novartis (Neoral((R))) have been developed. Some data on oral resorption are available for the new formulations. So far, however, only healthy volunteers or patients stable after kidney or liver transplantation have been investigated in clinical trials using these new formulations. Definite data on the resorption characteristics of the new galenic formulations of cyclosporin will come from the analysis of patients with liver transplants during the early post-transplant course receiving either cyclosporin-modified-Novartis or the new cyclosporin formulations.

Cyclosporin as baseline immunosuppression in solid organ transplantation. Publishing Authors By Initials

M Winkler,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Cyclosporin as baseline immunosuppression in solid organ transplantation. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: BioDrugs : clinical immunotherapeutics, biopharmac

VOLUME: 14

Page Numbers: 185-93

Journal Abbreviation:

ISSN: 1173-8804

DAY: 23

MONTH: Sep

YEAR: 2000

Cyclosporin as baseline immunosuppression in solid organ transplantation. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9705305

Cyclosporin as baseline immunosuppression in solid organ transplantation. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Cyclosporin as baseline immunosuppression in solid organ transplantation. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Cyclosporin as baseline immunosuppression in solid organ transplantation.

AFFILIATION: Klinik für Viszeral- und Transplantationschirurgie, Medizinische Hochschule, Hannover, Germany.

Country: New Zealand

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: BioDrugs

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Cyclosporin as baseline immunosuppression in solid organ transplantation Related Publications

• 3D reconstruction and processing of volumetric data in cryo-electron tomography.
• 3rd International conference on structure, dynamics and function of proteins in biological membranes.
• Alpha-synuclein tertiary contact dynamics.
• An integrated model of group psychotherapy for patients with fibromyalgia.
• Cyclosporin as baseline immunosuppression in solid organ transplantation.
• Equilibrium unfolding of the poly(glutamic acid)20 helix.
• Expanded reverse abdominoplasty for reconstruction of burns in the epigastric region and the inframammary fold in female patients.
• Fixation of the cervical spine using a titanium plate.
• Genome sequence of Avery's virulent serotype 2 strain D39 of Streptococcus pneumoniae and comparison with that of unencapsulated laboratory strain R6.
• Hedgehog signaling pathway is inactive in colorectal cancer cell lines.
• Heterotopic pregnancy after bilateral salpingectomy resulting in near-term delivery of a healthy infant.
• Image-derived input function for assessment of 18F-FDG uptake by the inflamed lung.
• Josephson effect in hybrid oxide heterostructures with an antiferromagnetic layer.
• Letter: Saline jet-assisted skin graft spreading.
• Mechanism of mRNA destabilization by the glmS ribozyme.
• Microtensile bond strength of resin-resin interfaces after 24-hour and 2-month soaking.
• Multiple cerebral cavernous malformations associated with extracranial mesenchymal anomalies.
• NPHS2 variation in sporadic focal segmental glomerulosclerosis.
• Novel POMGnT1 mutations define broader phenotypic spectrum of muscle-eye-brain disease.
• On the alliinase from garlic: participation of a flavine and inhibition by rotenone.
• Optimization of triarylimidazoles for Tie2: influence of conformation on potency.
• Probing folded and unfolded states of outer membrane protein a with steady-state and time-resolved tryptophan fluorescence.
• Probing the cytochrome c' folding landscape.
• Regulatory polymorphisms in the cyclophilin A gene, PPIA, accelerate progression to AIDS.
• Reprint of "Structural and mechanistic aspects of Amt/Rh proteins" [J. Struct. Biol. 158 (2007) 472-481].
• Site-specific collapse dynamics guide the formation of the cytochrome c' four-helix bundle.
• Structure Analysis of Eukovoside, A New Phenylpropanoid Glycoside from Euphrasia rostkoviana.
• The 1.3-A resolution structure of Nitrosomonas europaea Rh50 and mechanistic implications for NH3 transport by Rhesus family proteins.
• The teleost fish medaka (Oryzias latipes) as genetic model to study gravity dependent bone homeostasis in vivo.
• Two New Secoiridoid Glucosides from Syringa vulgaris.